Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > CombiMatrix Receives New $1.5 Million U.S. Air Force Contract

Abstract:
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has received a contract from the U.S. Air Force Research Laboratory for $1,476,000 to develop automated instrumentation that uses semiconductor microarray technologies for detecting chemical, biological and environmental hazards that can impact the health of deployed military personnel.

CombiMatrix Receives New $1.5 Million U.S. Air Force Contract

Mukilteo, WA | Posted on September 14th, 2009

"This funding will allow us to develop, and demonstrate an instrument platform that provides sample-to-answer capabilities," stated Dr. David Danley, Director of Homeland Security and Defense Programs at CombiMatrix. "Under previous Department of Defense contracts, we have developed diverse assays for identifying a variety of chemical and biological hazards using our semiconductor microarray with a small, handheld detector. By including sample preparation, these products can provide sophisticated detection and diagnostic capabilities in simple laboratory settings and austere field conditions."

Dr. Amit Kumar, President and CEO of CombiMatrix, stated, "This contract continues our multi-year collaboration with the U.S. Department of Defense (DOD). We have utilized DOD funding to develop dual-use technology for both military and civilian needs. Some of the products developed under such programs include our ElectraSense(R) Reader and Influenza Assay system, as well as
detection systems for a number of biological threats such as anthrax and plague. We are pleased that our military feels our technology is worthy of continued support."

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

####

About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. Combimatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory. Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

For more information, please click here

Contacts:
CombiMatrix Corporation
Amit Kumar, Ph.D., President & CEO
(425) 493-2000
Fax: (425) 493-2010
Hayden IR

Investor Relations Contact:
Jeffrey Stanlis, Partner
(602) 476-1821

Copyright © GlobeNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Photonic chip guides single photons, even when there are bends in the road February 16th, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

European & Korean Project To Demo World’s First 5G Platform During Winter Games February 15th, 2018

Govt.-Legislation/Regulation/Funding/Policy

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

Rutgers-Led Innovation Could Spur Faster, Cheaper, Nano-Based Manufacturing: Scalable and cost-effective manufacturing of thin film devices February 14th, 2018

Understanding brain functions using upconversion nanoparticles: Researchers can now send light deep into the brain to study neural activities February 14th, 2018

Sensors

Graphene on toast, anyone? Rice University scientists create patterned graphene onto food, paper, cloth, cardboard February 13th, 2018

Leti Chief Scientist Barbara De Salvo Will Help Kick Off ISSCC 2018 with Opening-Day Keynote: In Addition, Leti Scientists Will Present and Demo New Technology for Piezoelectric Energy Harvesting February 8th, 2018

Engineers develop flexible, water-repellent graphene circuits for washable electronics January 24th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Announcements

Photonic chip guides single photons, even when there are bends in the road February 16th, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

European & Korean Project To Demo World’s First 5G Platform During Winter Games February 15th, 2018

Homeland Security

A dash of gold improves microlasers: The precious metal provides a 'nano' solution for improving disease detection, defense and cybersecurity applications October 9th, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

Nanosensors on the alert for terrorist threats: Scientists interested in the prospects of gas sensors based on binary metal oxide nanocomposites November 5th, 2016

Nanobionic spinach plants can detect explosives: After sensing dangerous chemicals, the carbon-nanotube-enhanced plants send an alert November 2nd, 2016

Military

Graphene on toast, anyone? Rice University scientists create patterned graphene onto food, paper, cloth, cardboard February 13th, 2018

Silk fibers could be high-tech ‘natural metamaterials’ January 31st, 2018

Researchers use sound waves to advance optical communication January 22nd, 2018

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

New-Contracts/Sales/Customers

STMicroelectronics Selects GLOBALFOUNDRIES 22FDX® to Extend Its FD-SOI Platform and Technology Leadership : GF’s FDX technology will enable ST to deliver high-performance, low-power products for next-generation consumer and industrial applications January 9th, 2018

Solid State Laser manufacturer Lasertel Inc. purchases an Oxford Instruments ICPCVD advanced deposition solution for improved device performance November 3rd, 2017

GLOBALFOUNDRIES and Soitec Enter Into Long-term Supply Agreement on FD-SOI Wafers: Strategic milestone to help guarantee a secure, high-volume supply of FD-SOI technology September 20th, 2017

Probiotics: Novel biosynthetic tool to develop metallic nanoparticles: This research article by Dr. Nida Akhtar et al has been published in Recent Patents on Drug Delivery & Formulation, Volume 11, Issue 1, 2017 July 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project